BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu YC, Nguyen PA, Humayun A, Chien SC, Yang HC, Asdary RN, Syed-Abdul S, Hsu MH, Moldovan M, Yen Y, Li YJ, Jian WS, Iqbal U. Does long-term use of antidiabetic drugs changes cancer risk? Medicine (Baltimore) 2019;98:e17461. [PMID: 31577776 DOI: 10.1097/MD.0000000000017461] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Hayashi H, Matsumura K, Uemura N, Shiraishi Y, Sato H, Baba H. Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2023;15. [PMID: 36672448 DOI: 10.3390/cancers15020498] [Reference Citation Analysis]
2 Singh H, Sharma J, Sikarwar P, Kakkar AK. Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert Rev Clin Pharmacol 2023;16:39-47. [PMID: 36534928 DOI: 10.1080/17512433.2023.2161045] [Reference Citation Analysis]
3 Dobrică EC, Banciu ML, Kipkorir V, Khazeei Tabari MA, Cox MJ, Simhachalam Kutikuppala LV, Găman MA. Diabetes and skin cancers: Risk factors, molecular mechanisms and impact on prognosis. World J Clin Cases 2022; 10(31): 11214-11225 [DOI: 10.12998/wjcc.v10.i31.11214] [Reference Citation Analysis]
4 Chung CT, Lakhani I, Chou OH, Loy Lee TT, Dee C, Ng K, Wong WT, Liu T, Lee S, Zhang Q, Yung Cheung BM, Tse G, Zhou J. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study.. [DOI: 10.1101/2022.07.21.22277915] [Reference Citation Analysis]
5 Rokszin G, Kiss Z, Sütő G, Kempler P, Jermendy G, Fábián I, Szekanecz Z, Poór G, Wittmann I, Molnár GA. Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. Front Oncol 2021;11:725465. [PMID: 34778040 DOI: 10.3389/fonc.2021.725465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti Kumar V, Mishra AP, Sharifi-Rad J. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int 2021;21:499. [PMID: 34535145 DOI: 10.1186/s12935-021-02202-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Duan X, Wang W, Pan Q, Guo L. Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development. Front Oncol 2021;11:730038. [PMID: 34485159 DOI: 10.3389/fonc.2021.730038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Azeez TA, Folorunso SA, Eguzozie C, Adegboyega AA. Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental? Forum of Clinical Oncology 2021;12:74-81. [DOI: 10.2478/fco-2021-0014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]